

Prenatal Genetic Testing Beyond NIPT

CONTINUING MEDICAL EDUCATION

DATE April 26, 2021
TIME 7:30 p.m. – 8:30 p.m., SGT

- KEY POINTS
- **Genetic risks in pregnancies**
 - **When to choose NIPT?**
 - **When to think beyond**
 - **Prenatal Exome Sequencing**
 - Indications
 - Diagnostic yield
 - Case example



REGISTER

Major fetal structural anomalies occur in approximately 2 – 4 % of all pregnancies. Thanks to major advancements in emerging genetic technologies over the last decades, prenatal diagnostics are now more accessible and accurate than ever before. Join CENTOGENE's Dr. Peter Bauer, Chief Genomic Officer (CGO), and Dr. Maximilian Schmid, Chief Commercial Officer (CCO) Diagnostics, as they discuss the latest approaches to prenatal screenings, including Exome Sequencing, Genome Sequencing, and Microarrays.

Don't miss out on learning about the proven and practical approaches to caring for your patients in the prenatal setting. **Register today!**

SPEAKER

Peter Bauer, MD – Chief Genomic Officer (CGO), CENTOGENE



Combining clinical and medical understanding in genetic testing with an excellent knowledge of the latest scientific development, Peter heads CENTOGENE's Research and Development initiatives.

Peter is passionate about turning medical questions into a complete and fast analytical process, ensuring that the medically driven result is brought back to the clinician and the patient immediately.

He received his board certification in Human Genetics in 2006 and headed the Molecular Diagnostic Laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Additionally, he is Vice President of the German Society of Neurogenetics (DGNG). Peter has authored more than 140 publications in neurogenetics, oncogenetics, cardiogenetics, and sequencing technology.

MODERATOR

Maximilian Schmid, MD – Chief Commercial Officer (CCO) Diagnostics, CENTOGENE



Bringing over two decades of experience, Max has the overall responsibility of driving CENTOGENE's Diagnostic business strategy and growth. He joins CENTOGENE from Roche Diagnostics, where he most recently served as Global Head of Medical Affairs of its Sequencing Business Unit. Within this role, he developed and executed the medical strategy across disease areas, such as Oncology and Women's Health. He came to Roche following the acquisition of Silicon Valley startup Ariosa Diagnostics Inc., where after a successful career in academic medicine, he helped build a leading global NIPT business.

Furthermore, he holds a medical degree from the University of Vienna and is board-certified with habilitation in Obstetrics and Gynecology and sub-specialty training in Maternal-Fetal Medicine, as well as certification in Clinical Genetics.

SPONSORED BY:

SCIENCEWERKE DX
a division of Sciencewerke Pte Ltd

CENTOGENE
THE RARE DISEASE COMPANY

SUPPORTED BY:

Obstetrical & Gynaecological Society of Singapore

Sciencewerke DX is a division of Sciencewerke Pte Ltd

Phone: +65 (0)6777 1045

Fax: +65 (0)6777 3054

67 Ayer Rajah Crescent #04-21 Singapore 139950

www.sciencewerkedx.com

Phone: +49 (0)381 80 113 - 416

Fax: +49 (0)381 80 113 - 401

Email: customer.support@centogene.com

www.centogene.com